Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA

NCT05460832 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

248

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: MBS2320 5 mg
DRUG: MBS2320 20 mg
DRUG: MBS2320 40 mg
DRUG: Placebo

Sponsor

Modern Biosciences Ltd